REGN vs. AGN, AMGN, VRTX, GILD, ALXN, BIIB, ALNY, RPRX, BGNE, and NBIX
Should you be buying Regeneron Pharmaceuticals stock or one of its competitors? The main competitors of Regeneron Pharmaceuticals include Allergan (AGN), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), Alexion Pharmaceuticals (ALXN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Royalty Pharma (RPRX), BeiGene (BGNE), and Neurocrine Biosciences (NBIX).
Regeneron Pharmaceuticals (NASDAQ:REGN) and Allergan (NYSE:AGN) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, community ranking, earnings, dividends and profitability.
Regeneron Pharmaceuticals received 109 more outperform votes than Allergan when rated by MarketBeat users. However, 79.88% of users gave Allergan an outperform vote while only 66.59% of users gave Regeneron Pharmaceuticals an outperform vote.
Regeneron Pharmaceuticals has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500. Comparatively, Allergan has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.
83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.9% of Allergan shares are owned by institutional investors. 7.5% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Allergan shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Regeneron Pharmaceuticals has higher earnings, but lower revenue than Allergan. Allergan is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Regeneron Pharmaceuticals currently has a consensus price target of $989.36, suggesting a potential upside of 0.94%. Given Regeneron Pharmaceuticals' higher probable upside, equities analysts plainly believe Regeneron Pharmaceuticals is more favorable than Allergan.
Regeneron Pharmaceuticals has a net margin of 29.45% compared to Allergan's net margin of -15.44%. Regeneron Pharmaceuticals' return on equity of 16.83% beat Allergan's return on equity.
In the previous week, Regeneron Pharmaceuticals had 14 more articles in the media than Allergan. MarketBeat recorded 14 mentions for Regeneron Pharmaceuticals and 0 mentions for Allergan. Regeneron Pharmaceuticals' average media sentiment score of 0.53 beat Allergan's score of 0.00 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.
Summary
Regeneron Pharmaceuticals beats Allergan on 14 of the 18 factors compared between the two stocks.
Get Regeneron Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding REGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Regeneron Pharmaceuticals Competitors List
Related Companies and Tools
